Health-related quality of life and disease symptoms in postmenopausal women with HR⁺, HER2⁻ advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy

References

• NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 2.2013. Fort Washington, PA: National Comprehensive Cancer Network. Available at: www.nccn.com [Last accessed 8 May 2013]
   Google Scholar
• Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21:242-52
   PubMed Web of Science ®Google Scholar
• Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004;11:643-58
   PubMed Web of Science ®Google Scholar
• Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2:101-12
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005;23:1616-22
   PubMed Web of Science ®Google Scholar
• Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30:2718-24
   PubMed Web of Science ®Google Scholar
• Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-7
   PubMed Web of Science ®Google Scholar
• Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005;11:5319-28
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9
   PubMed Web of Science ®Google Scholar
• Afinitor (everolimus) tablets [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf [Last accessed 8 May 2013]
   Google Scholar
• Gotay CC, Lipscomb J, Snyder CF. Reflections on findings of the Cancer Outcomes Measurement Working Group: moving to the next phase. J Natl Cancer Inst 2005;97:1568-74
   PubMed Web of Science ®Google Scholar
• Gerber B, Freund M, Reimer T. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int 2010;107:85-91
   PubMed Web of Science ®Google Scholar
• Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 2008;27:32
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Piccart M, Rugo H, et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial. Cancer Res 2011;71(Suppl):105s-6s. Abstract S3-7
   Google Scholar
• Burris HA 3rd, Lebrun F, Rugo HS, et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 2013;119:1908-15
   PubMed Web of Science ®Google Scholar
• Piccart M, Noguchi S, Pritchard KI, et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial. J Clin Oncol 2012;30:21s. Abstract 559
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Black JT, Bordeleau LJ, et al. Health-related quality-of-life measurement in randomized clinical trials in breast cancer – taking stock. J Natl Cancer Inst 2003;95:263-81
   PubMed Web of Science ®Google Scholar
• Sprangers MA, Groenvold M, Arraras JI, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996;14:2756-68
   PubMed Web of Science ®Google Scholar
• Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual, 3rd edn. Brussels: European Organisation for Research and Treatment of Cancer, 2001
   Google Scholar
• Rubin DB. Inference and missing data. Biometrika 1976;63:581-92
   Web of Science ®Google Scholar
• Michiels B, Molenberghs G, Bijnens L, et al. Selection models and pattern-mixture models to analyse longitudinal quality of life data subject to drop-out. Stat Med 2002;21:1023-41
   PubMed Web of Science ®Google Scholar
• Little RJA. Pattern-mixture models for multivariate incomplete data. J Am Stat Assoc 1993;88:125-34
   Web of Science ®Google Scholar
• Hedeker D, Gibbons RD. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Methods 1997;2:64-78
   Web of Science ®Google Scholar
• Donaldson GW, Moinpour CM. Learning to live with missing quality-of-life data in advanced-stage disease trials. J Clin Oncol 2005;23:7380-4
   PubMed Web of Science ®Google Scholar
• Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664-70
   PubMed Web of Science ®Google Scholar
• Zhou X, Cella D, Cameron D, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat 2009;117:577-89
   PubMed Web of Science ®Google Scholar
• Yardley DA, Hortobagyi GN, Lebrun F, et al. Patient-reported physical, emotional, and social functioning in advanced breast cancer: insights from BOLERO-2. J Clin Oncol 2013;31:20s. Abstract 553
   Google Scholar
• Hedeker D. An introduction to growth modeling. In: Kaplan D, ed. Quantitative Methodology for the Social Sciences. Thousand Oaks, CA: Sage Publications, 2004
   Google Scholar
• Bottomley A, Biganzoli L, Cufer T, et al. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. J Clin Oncol 2004;22:2576-86
   PubMed Web of Science ®Google Scholar
• Helgeson VS, Tomich PL. Surviving cancer: a comparison of 5-year disease-free breast cancer survivors with healthy women. Psychooncology 2005;14:307-17
   PubMed Web of Science ®Google Scholar